Stem cell therapy improves condition of patients with type 2 diabetes

06/19/2014 | Australian Life Scientist

Type 2 diabetes patients who were treated with infusions of Mesoblast's mesenchymal precursor cells had greater reductions in blood sugar levels than those who received a placebo, according to a study presented at a meeting of the American Diabetes Association. The 61-patient midstage trial found that the cells were well-tolerated and that treatment was associated with a dose-dependent improvement in glycemic control.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD